



**ASX & MEDIA RELEASE**

**11 FEBRUARY 2016**

**MEDLAB SUPPORTS NEW FEDERAL LEGISLATION FOR MEDICAL CANNABIS**

Nutritional pharmaceutical company, Medlab Clinical Ltd (ASX: MDC), is supportive of new legislation introduced into federal parliament yesterday to allow cultivation of cannabis in Australia for medical or scientific purposes.

Health Minister, Ms Sussan Ley, said amendments to the *Narcotics Drugs Act 1967* would allow the controlled cultivation of cannabis for medicinal or scientific purposes through one single national licensing scheme – an Australian first.

This is intended to allow Australian patients and their doctors to access a safe, legal and reliable supply of medicinal cannabis products for the management of painful and chronic conditions.

Ms Ley said the Turnbull Government had worked closely with the states and territories, law enforcement agencies and other stakeholders over the past eight weeks to ensure this legislation was “robust” before bringing it to Parliament to give it the best chance of a smooth passage.

In July 2015, Medlab became one of the first commercial entities in New South Wales to receive NSW government approval for use of cannabis in medical research.

Since then Medlab has developed a therapy for pain management. This research is being led by Professor Luis Vitetta, Medlab Clinical’s Director of Medical Research and Adjunct Professor at the University of Sydney Medical School.

This therapy has been proposed for human clinical trials for which Medlab expects to receive ethics approval shortly, a prerequisite for attaining other government and regulatory approvals to commence human trials.

Medlab’s therapy is intended to be used with its NanoCelle™ delivery platform, which administers therapies in a mouth spray, achieving controlled dosing and more effective absorption into the human system.

Medlab Clinical CEO, Mr Sean Hall, said developing Medlab’s pain management therapy in an environment of government support for medical use of cannabis could reduce clinical trial time, and thus accelerate the delivery of a cannabis product in a controlled dose for targeted treatment into the community.

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)

**FOR FURTHER INFORMATION:** MR SEAN HALL, CEO, MEDLAB CLINICAL  
TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

**ISSUED BY:** HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL  
TEL +61 2 9286 1226 OR +61 468 960 457, [marcha.vandenheuvel@hkstrategies.com](mailto:marcha.vandenheuvel@hkstrategies.com)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based biotechnology company, with a certified biologics facility in Sydney and sales arms in Australia and California (InMed Technologies). The research focus is on the role bacteria in the gastrointestinal tract play in health and disease, in five health areas: obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. Medlab develops and sells nutraceuticals in the US and Australia to support drug discovery and development of new medicines involving bacteria (pharmacobiotics). Medlab currently has 9 patents pending and 6 in draft, 15 published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.